

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genor Biopharma Holdings Limited
嘉和生物藥業(開曼)控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6998)

ANNOUNCEMENT
RESIGNATION OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of Genor Biopharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Zhou Joe Xin Hua (“**Dr. Zhou**”) has tendered his resignation as an executive Director due to his decision to devote more time on his other businesses, with effect from 15 April 2022. Dr. Zhou has also resigned from his role as President of the Group.

Dr. Zhou has confirmed that he has no claim against the Company in respect of his resignation and there is no disagreement between him and the Board; and there are no matters that need to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company in relation to his resignation.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Zhou for his valuable contribution to the Company during his tenure of office.

By Order of the Board
Genor Biopharma Holdings Limited
Dr. GUO Feng
Chief Executive Officer and Chairman

Hong Kong, 14 April 2022

As at the date of this announcement and following the above resignation of Director, the Board comprises Dr. GUO Feng as executive Director; Dr. LYU Dong, Mr. CHEN Yu and Dr. NI Lin as non-executive Directors; and Mr. ZHOU Honghao, Mr. FUNG Edwin and Mr. CHEN Wen as independent non-executive Directors.